CNR1 and chronic kidney disease: In their study, Udi et al. [77] showed that not only was MRI-1867 effective in treating obesity-induced CKD, it was more effective than the monotherapy of a peripherally restricted CB1 antagonist, JD5037, as it simultaneously inhibited two major mediators.